3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Lymphoid
1
Genitourinary
1
CNS
1
Conditions
Prostatic Neoplasms
8
Urinary Bladder Neoplasms
2
Neoplasms
2
Melanoma
2
Kidney Neoplasms
2
Carcinoma, Renal Cell
2
Wilms Tumor
1
Small Cell Lung Carcinoma
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Pain
1
Neuroectodermal Tumors, Primitive
1
Neuroblastoma
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasm Metastasis
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Lung Neoplasms
1
Hodgkin Disease
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
Radiosurgery
9
Magnetic Resonance Spectroscopy
6
pembrolizumab
4
Radiotherapy
4
Nivolumab
4
Fluorodeoxyglucose F18
4
cabozantinib
3
Specimen Handling
3
Paclitaxel
3
Melphalan
3
Ipilimumab
3
Granulocyte Colony-Stimulating Factor
3
Filgrastim
3
Busulfan
3
lenvatinib
2
entrectinib
2
cediranib
2
Thiotepa
2
Sunitinib
2
Radiation
2
Peripheral Blood Stem Cell Transplantation
2
Injections
2
Ifosfamide
2
FAPI-46
2
Etoposide
2
Carboplatin
2
Bone Marrow Transplantation
2
Bevacizumab
2
2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide
2
trioctyl phosphine oxide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Brain Neoplasms
×
Genistein
×
Genitourinary
×
Clear all
NCT02624388
2024-05-06
UVA-Gen001
University of Virginia
Phase 2
Terminated
4 enrolled
16 charts